The Claim
Among adults with obesity prescribed semaglutide for 12 months, significant improvements in metabolic markers, lipid profiles, blood pressure, liver function tests, and cardiovascular disease risk outcomes were observed, suggesting an association between semaglutide use and broader cardiometabolic benefit.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with obesity taking semaglutide for 12 months, measurable improvements were seen in blood sugar, cholesterol, blood pressure, liver enzymes, and cardiovascular risk indicators.
See the scientific wording
Among adults with obesity prescribed semaglutide for 12 months, significant improvements in metabolic markers, lipid profiles, blood pressure, liver function tests, and cardiovascular disease risk outcomes were observed, suggesting an association between semaglutide use and broader cardiometabolic benefit.
Losing weight reduces fat stored in the wrong places like the liver and around organs, which lowers inflammation and lets the body use insulin better, improving blood sugar, cholesterol, and blood pressure.
What the research says
1 studyStudy: Weight loss and cardiovascular disease risk outcomes of semaglutide: a one-year multicentered study
People with obesity who took semaglutide for a year lost weight and also saw their blood sugar, cholesterol, blood pressure, and liver health get better — meaning the medicine helped their whole body, not just their weight.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.